Real-world evidence strengthens case for oral antivirals in older COVID-19 patients
Amid ongoing hospitalisation, a leading GP calls for a focus on early testing and treatment
This content has been independently produced by AusDoc and made possible through sponsorship from MSD.
Fresh evidence has emerged supporting the use of oral antivirals to prevent complications in older, at-risk community patients.
A real-world study of almost 24,000 patients shows a significant reduction in the risk of hospitalisation and death in this patient cohort when prescribed molnupiravir (Lagevrio) within five days of symptom onset.
The results also demonstrate a higher effectiveness rate when compared with earlier reports.
